AZN250103C75000
- 0.01
- 0.000.00%
AstraZeneca Newsroom
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
AstraZeneca PLC Stock Flat Friday
AstraZeneca (AZN.US) has initiated a Phase III clinical trial for the PD-1/TIGIT dual antibody.
AstraZeneca (AZN.US) has launched Phase III clinical trials for its PD-1/TIGIT dual antibody.
AstraZeneca Call Volume Above Normal and Directionally Bullish
Unusual Options Activity: NCLH, AZN and Others Attract Market Bets, NCLH V/OI Ratio Reaches 55.6
AstraZeneca Announces Share Capital and Voting Rights Update
AstraZeneca (AZN.US) "Osimertinib" has been approved for a new indication in China.
On January 2nd, the National Medical Products Administration website showed that AstraZeneca (AZN.US)'s application for the new indication of Osimertinib has officially been approved.
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
Hutchmed Says China's Medicines Regulator Accepts NDA With Priority Review for Orpathys, Tagrisso Combination
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
Reported Wednesday, HUTCHMED And AstraZeneca's ORPATHYS-TAGRISSO Therapy Advances In China With Priority NDA Status For MET-Amplified Lung Cancer
Takeda-backed Ascentage Pharma Files for $100M IPO
AstraZeneca (AZN.US) has a potentially significant ADC approved for the treatment of breast cancer.
The antibody-drug conjugate (ADC) Datroway (datopotamab deruxtecan), jointly developed by Daiichi Sankyo and AstraZeneca (AZN.US), has been approved in Japan.
Morgan Stanley: Personalized cancer vaccines and ADCs will become the main catalysts in the oncology treatment Industry by 2025.
Morgan Stanley stated in a recent research report that personalized cancer vaccines and antibody-drug conjugates (ADCs) will become one of the major innovations in cancer biotechnology next year.
Is AstraZeneca PLC (AZN) Among the U.K. Dividend Aristocrats for 2024?
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Astrazeneca (AZN) Stock Moves -0.39%: What You Should Know
Daiichi Sankyo Gets Japanese Approval for Datroway
Here's Why Astrazeneca (AZN) Is a Strong Value Stock
Syncona: Achilles Announces Sale Of Technology Assets To AstraZeneca - Quick Facts